All In Biotech

Drug Trial Radar · NCT02586805

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

HELP Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX-2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)

Last checked: Nov 20, 2026Latest source record: Jun 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 125 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

125

Actual

Start

Mar 3, 2016

Primary completion

Apr 13, 2017

Study completion Apr 13, 2017

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
Collaborators
Dyax Corp.
First posted
Oct 26, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

Conditions

  • Hereditary Angioedema (HAE)

Interventions

  • DX-2930 - 300mg/2wkDrug

    300 mg DX-2930 administered every 2 weeks by subcutaneous injection.

  • DX-2930 - 300mg/4wkDrug

    300 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.

  • DX-2930 - 150mg/4wkDrug

    150 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.

  • PlaceboDrug

    Placebo administered every 2 weeks by subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Investigator Confirmed Hereditary Angioedema (HAE) Attacks During Treatment PeriodTime frame: From Day 0 to Day 182

Locations

41 sites in 7 countries. Site status is shown where the registry gives one.

  • Clinical Research Center of Alabama, LLC

    Birmingham, Alabama

  • Medical Research of Arizona

    Scottsdale, Arizona

  • UC San Diego School of Medicine

    San Diego, California

  • AIRE Medical of Los Angeles

    Santa Monica, California

  • Allergy & Asthma Clinical Research

    Walnut Creek, California

  • IMMUNOe International Health & Research Centers

    Centennial, Colorado

  • Asthma and Allergy Associates, P.C.

    Colorado Springs, Colorado

  • University of South Florida

    Tampa, Florida

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Institute of Asthma & Allergy, P.C.

    Chevy Chase, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan Hospital and Health System

    Ann Arbor, Michigan

  • Midwest Immunology Clinic

    Plymouth, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Hudson-Essex Allergy, LLC

    Belleville, New Jersey

  • Atlantic Research Center, LLC

    Ocean City, New Jersey

  • Winthrop University Hospital

    Mineola, New York

  • The Mount Sinai Medical Center

    New York, New York

  • American Health Research

    Charlotte, North Carolina

  • Duke Asthma, Allergy and Airway Center

    Durham, North Carolina

  • Bernstein Clinical Research Center, LLC

    Cincinnati, Ohio

  • Optimed Research, LTD

    Columbus, Ohio

  • Toledo Institute of Clinical Research

    Toledo, Ohio

  • Penn State Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • Austin Regional Clinic

    Austin, Texas

  • AARA Research Center

    Dallas, Texas

  • Intermountain Clinical Research

    Draper, Utah

  • Allergy Associates of Utah

    Murray, Utah

  • Virginia Commonwealth University

    Richmond, Virginia

  • Marycliff Allergy Specialists

    Spokane, Washington

  • Children's Hospital of Wisconsin

    Milwaukee, Wisconsin

  • Ottawa Allergy Research Corporation

    Ottawa, Ontario, Canada

  • Gordon Sussman Clinical Research Inc.

    Toronto, Ontario, Canada

  • Clinique Specialisee en Allergie de la Capitale

    Québec, Quebec, Canada

  • Charité - University of Berlin

    Berlin, Germany

  • Hautklinik und Poliklinik der Universitätsmedizin

    Mainz, Germany

  • HZRM Hamophilie-Zentrum Rhein Main

    Mörfelden-Walldorf, Germany

  • Hospital L. Sacco, Milan University

    Milan, Italy

  • Triumpharma

    Amman, Jordan

  • Sociedad Alergologica

    San Juan, PR, Puerto Rico

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.